Peptide Therapeutics Market

1
Peptide Therapeutics Market To Reach USD 50.60
Billion By 2026
www.reportsanddata.com
sales_at_reportsanddata.com
2
Market Summary
Increased incidence of cancer, presence of active
product range, cumulative acceptance of sedentary
lifestyle leading to rising of metabolic
diseases, emerging healthcare markets, are key
factors contributing to high CAGR of Peptide
Therapeutics market during the forecast
period. Market Size USD 25.35 Billion in 2018,
Market Growth - CAGR of 9.0, Market Trends
Advancements in Peptide Conjugates, and
technological innovations in Peptide Therapeutics.
3
Our Approach
Market Summary

• The global Peptide Therapeutics market was valued
  at USD 25.35 billion in 2018 and is expected to
  reach USD 50.60 billion by the year 2026, at a
  CAGR of 9.0. Peptide drugs are used as
  replacement therapies which supplements peptide
  hormones when the endogenous levels tend to
  decrease. The first peptide therapeutic was used
  to treat diabetic patients in the 19th century.
  The approval for 60 peptides has been granted,
  with the clinical global administration in the
  United States, Europe, and Japan. These drugs are
  used as drug target moiety for cancer, metabolic
  disorders, cardiovascular disease.
• To improve efficiency, conjugates became a boon
  to alter the properties of proteins. The
  Polyethylene Glycol (PEG) conjugation, lipids,
  and proteins have been used for extending the
  half-life. In recent years, cell-penetrating
  peptides, termed as ideal transporters, are
  responsible for assisting the therapeutic cargos
  in a non-toxic and simple manner being protein,
  oligonucleotides, nanoparticles. They are
  currently used in cancer therapy due to its
  potent and quick delivery.
• Specific problems and restraints are shown by
  peptide therapeutics. The drawbacks are short
  plasma life and the inability of the functioning
  of oral bioavailability. By increasing the drug
  stability and peptide formulation, the peptide
  therapeutics can be taken in an oral form
  quickly.
• Request for a sample of this research report _at_
  https//www.reportsanddata.com/sample-enquiry-form
  /2770

4
Our Approach
Market Summary

• Further key findings from the report suggest
• The peptide therapeutics market is expected to
  reach USD 50.59 billion by the year 2026 at a
  CAGR of 9.0, according to the forecast period.
• Kallyope, a U.S based company, and Novo Nordisk,
  a Denmark based Company, entered into a research
  collaboration and agreement to discover novel
  therapeutics for treating obesity and diabetes in
  June 2018.
• North America has the largest market share of
  38.2 in the year 2018. Its increased dominance
  in the market is due to the increased investments
  of Research and Development, high incidence of
  cancer, and increased demand for healthcare
  expenditure. The advent of Peptide conjugates
  will also further drive a rapid increase in the
  market.
• The solid-phase peptide synthesis is expected to
  reach USD 22.6 billion by the year 2026, showing
  a good growth market in the year 2026.
• Hybrid technology is expected to grow with a CAGR
  of 8.8 in 2026.
• To identify the key trends in the industry, click
  on the link below https//www.reportsanddata.com/
  report-detail/peptide-therapeutics-market

5
Our Approach
Market Summary

• Key participants include Sanofi (Australia), Teva
  Inc (Israel), Novo Nordisk Inc, (Denmark), Takeda
  (Japan), Eli Lily (United States), Astra Zeneca
  (U.K.), Novartis (Switzerland), Shire (U.S.)
  Abbvie (U.S.), Ipsen (France) Allergen (Ireland
  ), Ferring (Switzerland), Merck (United States),
  The Medicines (United States), Roche
  (Switzerland) Johnson and Johnson (United
  States).
• For the purpose of this report, Reports and Data
  has segmented the Peptide Therapeutics
  market based on Route of Administration, Product
  Type, Type of Manufacturers, Application,
  Synthesis, Regional Outlook
• Route of Administration (Revenue in Million USD
  20162026)
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others
• Product Type Outlook (Revenue in Million USD
  20162026)
• Generic
• Innovative

6
Our Approach
Market Summary

• Application Outlook (Revenue in Million USD
  20162026)
• Cancers
• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others
• Order Now  https//www.reportsanddata.com/checkou
  t-form/2770

7
About Us
Our Approach
About Us

• Reports and Data is a market research and
  consulting company that provides syndicated
  research reports, customized research reports,
  and consulting services. Our solutions purely
  focus on your purpose to locate, target and
  analyze consumer behavior shifts across
  demographics, across industries and help clients
  make a smarter business decision. We offer market
  intelligence studies ensuring relevant and
  fact-based research across a multiple industries
  including Healthcare, Technology, Chemicals,
  Power, and Energy. We consistently update our
  research offerings to ensure our clients are
  aware about the latest trends existent in the
  market. Reports and Data has a strong base of
  experienced analysts from varied areas of
  expertise.
• Contact Us
• John Watson
• Head of Business Development
• Reports And Data Web www.reportsanddata.com
• Direct Line 1-212-710-1370
• E-mail sales_at_reportsanddata.com